Dr. Lilenbaum on the Clinical Implications of the FDA Approval of Lurbinectedin in SCLC
Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.
Dr. Lilenbaum on the Challenges of Integrating Telehealth Services in Lung Cancer
Rogerio C. Lilenbaum, MD, discusses the challenges of integrating telehealth services in lung cancer.
Dr. Lilenbaum on Future Directions With Immunotherapy in Lung Cancer
Rogerio C. Lilenbaum, MD, discusses the promising future direction of immunotherapy in patients with advanced lung cancer.
Dr. Lilenbaum on the Rise of Immunotherapy in NSCLC
Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.
Dr. Lilenbaum on PD-L1 as a Predictive Biomarker for Immunotherapy in Lung Cancer
Rogerio C. Lilenbaum, MD, discusses using PD-L1 as a predictive biomarker for immunotherapy and the search for additional biomarkers in lung cancer.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512